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CAP = community-acquired pneumonia; CMV = conventional mechanical ventilation; HAP = hospital-acquired pneumonia; HCAP = health-care-
associated pneumonia; NIV = non-invasive ventilation; PTC = protected telescoping aspiration; VAP = ventilator-associated pneumonia.
Available online http://ccforum.com/content/10/1/116
Abstract
Respiratory failure is one of the leading admission diagnoses on
the critical care unit, and the journals have reflected this over the
past few months. An understanding of the aetiology of pulmonary
sepsis is important but your choice of ventilator gas humidification
system is not. There are prophecies of more pandemics, but panic
is futile because survival is all down to your genes.
Health-care-associated pneumonia (HCAP) refers to a
pulmonary infection that develops in individuals recently
hospitalised, or undergoing renal replacement therapy or other
long-term out-patient care. Over the past few years it has been
postulated that this reflects a distinct group of pathogens with
consequent implications for therapy and also on outcome.
However, no study had looked at the pathogens of both
HCAP and community-acquired pneumonia (CAP) and
compared them with those of hospital-acquired pneumonia
(HAP) and ventilator-associated pneumonia (VAP).
Kollef et al. [1] have attempted to do this by retrospective
analysis of a large USA database of culture-positive
pneumonia, in 59 US centres over a 1-year period. The study
defined 4,543 positive pneumonias, of which 2,221 were
CAP, 988 HCAP, 853 HAP and 499 VAP. The results
showed that patients with HCAP were slightly older than
those with CAP but were broadly similar to those with HAP.
Half of the patients with HCAP came from nursing homes.
Illness severity was almost identical in both HCAP and VAP,
but was higher than in HAP and CAP. Bacterial pathogen
identification showed a high rate of Staphylococcus aureus
infection in all types of pneumonia but this may be an artefact;
however, also of interest was the low rate of pneumococcal
infection in CAP. Overall, bacterial species in HCAP were
broadly similar to those in HAP and VAP; Pseudomonas
accounted for just over 25% and methicillin-resistant
S. aureus 56%, with the rest made up of the usual Gram-
negative types. It was also noted that patient mortality for
HCAP was similar to that for HAP but higher than that for
CAP and lower than that for VAP.
The authors suggest that HCAP is a distinct entity from CAP
and should be treated as a hospital-acquired type of infection
from first presentation; the paper certainly supports the recently
published guidelines from the American Thoracic Society [2].
Staying with the pulmonary sepsis theme, Lacherade et al. [3]
shed further light on the debate over which factors may
influence the development of VAP, in particular the use of
differing humidification devices. This five-centre prospective
trial randomised 369 unselected patients who had required
ventilation for more than 48 hours, to receive treatment with
either a heated humidifier or a heat and moisture exchanger
during their stay. They showed no difference between the
treatments in incidence of VAP. Given previous data on this
subject it increasingly appears that the mode of respiratory
gas humidification is not critical.
The optimal specimen collection technique for the diagnosis
of VAP continues to be strongly debated. The paper by Brun-
Buisson et al. [4] looked at 68 patients with clinically apparent
VAP and prospectively performed blinded endotracheal
aspiration, blinded protected telescoping aspiration (PTC) and
bronchoscopic aspiration. Their results confirmed that
bronchoscopic aspiration provides the best cultures with
fewer false positives, with PTC being close behind. However,
endotracheal aspiration produced more false positives. This
means that the use of PTC can be used to obtain specimens
for the diagnosis of VAP and to guide therapy, and avoids the
need for a more invasive procedure and expensive equipment.
Finally on the respiratory theme, the role of non-invasive
ventilation (NIV) makes another appearance [5]. This paper
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compared the role of NIV with mechanical ventilation for
patients with acute respiratory failure from all causes who
fulfilled defined criteria for conventional mechanical
ventilation (CMV). A total of 64 patients were randomised, 31
to NIV and 33 to CMV, with 18 in the NIV group converting to
CMV. The mortality rate in the NIV group was 23%,
compared with 39% in the CMV group; complication rates
and durations of ventilation were similar. They also showed
that patients who did not respond to NIV did no worse overall
than those who received CMV from the start, and of interest
is the finding that all patients with pneumonia who underwent
NIV required CMV, a finding consistent with other studies. As
identified in the accompanying editorial [6], the study
numbers are small, particularly given the all-cause inclusion
criteria and as such interpretation of results should be
cautious.
The world recently seems to be an ever more dangerous
place, with increasing reason to be troubled by apocalyptic
nightmares. There is a superbug near you – be quite sure of it –
and it will probably try to kill you given half a chance.
Methicillin/vancomycin-resistant  S. aureus, severe acute
respiratory syndrome, pandemic and avian influenza have
dominated both the medical and lay press. The antecedents
of these organisms are well known to us, but it seems they
have started taking steroids and going to the gym a lot. There
is now mounting evidence that Clostridium difficile has
undergone a similar process. C. difficile, a spore-forming
Gram-positive anaerobic bacillus, has been recognised as the
causative agent of an antibiotic-associated colitis since the
mid-1970s. Given appropriately altered colonic flora this
bacterium will replicate and produce endotoxins (classically A
and B) causing a spectrum of disease from troublesome
watery diarrhoea to life-threatening pseudomembranous
colitis, depending largely on host characteristics such as age
and severity of underlying disease, therefore making its
incidence on the intensive care unit particularly high.
Furthermore, outbreaks were largely isolated to individual
wards or institutions. However, in recent years much larger
outbreaks in both North America and Europe have suggested
increased prevalence, resistance and virulence of C. difficile.
This raises the ugly spectre of an epidemic strain, and leads
us to ask why this has occurred, whether it is spontaneous
genetic mutation or a change in medical practice, and
whether we can do anything about it. Two recently published
papers with an accompanying editorial address some of
these issues [7–9].
The work of Mcdonald et al. [7] consists of an impressively
detailed microbiological survey of C. difficile outbreaks
across six states in the United States. Genetic and
toxicological profiles were compared with those from a
historical database of C. difficile obtained before 2001. In the
second paper a research group in Quebec [8] performed a
prospective surveillance of 12 institutions to determine the
incidence of hospital-acquired C. difficile-associated diarrhoea
and its associated risk factors. Isolates were also typed. The
results from the two studies were largely corroborative:
1. A previously uncommon strain of C. difficile has markedly
increased in incidence.
2. It is characterised by the production of a new toxin
(binary toxin), a partial deletion of the tcdC gene, which
normally downregulates toxin A and B production, and
increased resistance to fluoroquinolones.
3. Morbidity and mortality, particularly among the elderly,
are increasing compared with outbreaks in the 1980s
and 1990s.
4. Risk factors include exposure to fluoroquinolones and
cephalosprins.
A precise scientific link between the suggested virulence
factors (binary toxin and tcdC partial deletion) and severity of
disease is yet to be made. But the emergence of this relatively
new strain of C. difficile concomitant with increased severity
and prevalence of disease must be a cause for concern. In
answer to the question ‘What can we do?’ the accompanying
editorial [9] suggests that the following are essential:
1. Continued microbiological surveillance of disease
outbreaks, along with early diagnosis and treatment.
2. Scrupulous infection control practice, above and beyond
the normal, by all in contact with at risk patients.
3. The use of soap and water for hand washing given spore
resistance to alcohol preparations.
4. Regular institutional review of antimicrobial stewardship,
with early de-escalation of broad-spectrum antibiotics
wherever possible.
Finally, presuming that you have kept up with The Lancet
recently, you will be hoping that your mitochondrial DNA is of
the haplogroup H variety. A group in Newcastle analysed
mitochondrial DNA in 150 sequential adult admissions to the
intensive care unit with a diagnosis of severe sepsis, the
primary outcome measure being survival at 180 days [10].
Using logistical regression analysis they demonstrated that
haplogroup H was an independent predictor of survival,
patients with haplogroup H being 2.12 (95% confidence
interval 1.02 to 4.43) times more likely to be alive at 180
days. The authors propose that this finding might be
explained by the enhanced respiratory chain activity
associated with this haplotype, citing cellular dysoxia
secondary to mitochondrial dysfunction as a key factor in
sepsis-induced organ dysfunction. Interestingly, haplogroup
H patients generated significantly higher temperatures than
patients with differing haplogroups. Fortunately, H is the
commonest haplogroup, accounting for about 44% of
patients in this study. The authors suggest that mitochondrial
DNA haplotyping offers a new means of risk stratification in
severe sepsis, although further work is clearly needed to
identify possible therapeutic avenues.
Competing interests
The author(s) declare that they have no competing interests.Page 3 of 3
(page number not for citation purposes)
References
1. Kollef MH, Shorr A, Tabak Y, Gupta V, Liu LZ, Johannes RS: Epi-
demiology and outcomes of health-care-associated pneumo-
nia: results from a large US database of culture positive
pneumonia. Chest 2005, 128:3854-3862.
2. Niederman MS, Craven DE, Bonten MJ, Chastre J, Craig WA,
Fagon JY, Hall J, Jacoby GA, Kollef MH, Luna CM, et al.: Guide-
lines for the management of adults with hospital acquired,
ventilator associated and healthcare-associated pneumonia.
Am J Respir Crit Care Med 2005, 171:388-416.
3. Lacherade JC, Auburtin M, Cerf C, van de Louw A, Soufir L,
Rebufat Y, Rezaiguia S, Ricard JD, Lellouche F, Brun-Buisson C,
et al.: Impact of humidification systems on ventilator associ-
ated pneumonia. Am J Respir Crit Care Med 2005, 172:1276-
1282.
4. Brun-Buisson C, Fartoukh M, Lechapt E, Honoré S, Zahar JR, Cerf
C, Maitre B: Contribution of blinded, protected quantitative
specimens to the diagnostic and therapeutic management of
ventilator associated pneumonia. Chest 2005, 128:533-544.
5. Honrubia T, López FJ, Franco N, As M, Guevara M, Daguerre M,
Alía I, Algora A, Galdos P: Noninvasive vs conventional
mechanical ventilation in acute respiratory failure: a multicen-
ter, randomised controlled trial. Chest 2005, 128:3916-3924.
6. Garpestead E, Hill N: Non-invasive ventilation for acute respi-
ratory failure: but how severe? Chest 2005, 128:3790-3791.
7. Mcdonald CL, Killgore GE, Thompson A, Owens RC, Kazakova
SV, Sambol SP, Johnson S, Gerding DN: An epidemic, toxin
gene-variant strain of Clostridium difficile. N Engl J Med 2005,
353:2433-2441.
8. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S,
Bourgault AM, Nguyen T, Frenette C, Kelly M, et al.: A predomi-
nantly clonal multi-institutional outbreak of Clostridium diffi-
cile-associated diarrhea with high morbidity and mortality. N
Engl J Med 2005, 353:2442-2449.
9. Bartlett JG, Perl TM: The new Clostridium difficile – what does
it mean? N Engl J Med 353:2503-2504.
10. Baudouin SV, Saunders D, Tiangyou W, Elson JL, Poynter J, Pyle
J, Keers S, Turnbull DM, Howell N, Chinnery PF: Mitochondrial
DNA and survival after sepsis: a prospective study. Lancet
2005, 366:2118-2121.
Available online http://ccforum.com/content/10/1/116